Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C) Meeting Abstract
| Authors: | Abramson, J. S.; Straus, D.; Bartlett, N.; Burke, J. M.; Lynch, R. C.; Domingo‐Domenech, E.; Hess, B.; Schuster, S.; Linhares, Y.; Ramchandren, R.; Gandhi, M.; Mowat, R.; Shah, H.; Jurczak, W.; Re, A.; Hahn, U.; Prince, H. M.; Ho, L.; Guo, W.; Jain, S. |
| Abstract Title: | Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C) |
| Meeting Title: | 17th International Conference on Malignant Lymphoma (ICML) |
| Journal Title: | Hematological Oncology |
| Volume: | 41 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Jun 13-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2023-06-01 |
| Start Page: | 353 |
| End Page: | 355 |
| Language: | English |
| DOI: | 10.1002/hon.3164_254 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 254 -- Source: Cinahl |
